Relmada Therapeutics Inc RLMD 深 沪
已收盘 03-27 16:00:00 美东时间
6.41
-0.130
-1.99%
华盛通- 最 高7.51
- 今 开6.46
- 成交量 51.87万股
- 最 低 4.23
- 昨 收 6.54
- 总市值 18.87万
- 52周最高 7.51
- 市盈率 静 --
- 换手率 1762.42%
- 52周最低 0.243
- 委 比 19.35%
- 总股本 2.94万
- 历史最高 54.00
- 量 比 0.52
- 振 幅 50.15%
- 历史最低 0.2404
- 每 手 1
- 风险率 1.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For March 19, 2026
Companies Reporting Before The Bell • Neuraxis (AMEX:NRXS) is projected to repo...
03-19 19:11
Why Is Relmada Therapeutics Stock Soaring Monday?
Relmada Therapeutics shares rise on promising interim data from Phase 2 trial of NDV-01 for non-muscle invasive bladder cancer.
03-09 20:48
Market-Moving News for March 9th
HIMS: 54% | Novo Nordisk And Hims & Hers End Bitter Legal Feud With Surprise Weight-Loss Drug Deal: Report RLMD: 80% | Relmada Therapeutics Announces 12-month Interim Data From Its
03-09 19:30
Relmada Therapeutics Announces Private Placement Of $160M
Pursuant to the terms of the securities purchase agreement, Relmada is selling an aggregate of (i) 29,474,569 shares of its common stock ("Common Stock") at a purchase price of $4.75 per share and (ii) pre-funded
03-09 19:16
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
2025-11-13 19:11
Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology
Relmada Therapeutics appoints Raj S. Pruthi, MD as Chief Medical Officer for Urology to lead the development of NDV-01 for non-muscle invasive bladder cancer (NMIBC). Dr. Pruthi, with extensive expertise in urologic oncology and clinical trials, is crucial for advancing NDV-01's Phase 3 trial, expected to begin in H1 2026. Positive Phase 2 data showed promising results with GEM/DOCE sustained release formulation, offering improved response rates and tolerability for NMIBC patients.
2025-06-17 11:00
Jefferies Upgrades Relmada Therapeutics to Buy, Raises Price Target to $13
Jefferies analyst Andrew Tsai upgrades Relmada Therapeutics (NASDAQ:RLMD) from Hold to Buy and raises the price target from $3.5 to $13.
2024-09-17 20:46
Relmada Therapeutics Files For Mixed Shelf Offering Of Up To $250M
Relmada Therapeutics Files For Mixed Shelf Offering Of Up To $250M
2024-08-31 04:30
